BridgeBio Pharma, Inc. (BBIO)
65.32
-0.81
(-1.22%)
USD |
NASDAQ |
May 18, 16:00
65.36
+0.04
(+0.06%)
After-Hours: 20:00
BridgeBio Pharma Research and Development Expense (Quarterly) : 126.64M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Mirum Pharmaceuticals, Inc. | 97.84M |
| Pfizer Inc. | 2.452B |
| Insmed, Inc. | 209.48M |
| Alnylam Pharmaceuticals, Inc. | 364.87M |
| Vanda Pharmaceuticals, Inc. | 28.44M |